N@N

Market Maker Surveillance Report. ACUR, STXS, COOL, SOMX, ESYS, BGMD, Winning Stocks With Lowest Price Friction For Tuesday, D

December 11, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3925 companies with "abnormal" market making, 3585 companies with positive Friction Factors and 2095 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Acura Pharmaceuticals Inc (NASDAQ:ACUR), Stereotaxis Inc (NASDAQ:STXS), MAJESCO ENTERTAINMENT COMPANY (NASDAQ:COOL), Somaxon Pharmaceuticals Inc (NASDAQ:SOMX), Elecsys Corp (NASDAQ:ESYS), BG Medicine Inc (NASDAQ:BGMD). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  ACUR    $1.030    42.04%    5,059,110    50.09%    4,997,775    49.48%    61,335       595     
  STXS    $0.230    16.79%    103,322      75.89%    32,830       24.11%    70,492       3,065   
  COOL    $0.260    29.04%    767,752      55.29%    620,929      44.71%    146,823      5,647   
  SOMX    $1.180    80.27%    1,128,369    50.74%    1,092,291    49.11%    36,078       306     
  ESYS    $0.790    23.17%    74,651       54.52%    61,969       45.26%    12,682       161     
  BGMD    $2.170    163.16%   4,620,642    50.96%    4,437,543    48.94%    183,099      844     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows ACUR with a dollar gain Tuesday of $1.03000 and a Friction Factor of 595 shares. That means that it only took 595 more shares of buying than selling to move ACUR higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

Acura Pharmaceuticals Inc (NASDAQ:ACUR) - Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion Technology, Impede Technology, and other technologies. Its Aversion Technology is a proprietary platform technology providing abuse deterrent features and benefits to orally administered pharmaceutical drug products containing abusable active ingredients, such as tranquillizers, stimulants, sedatives, decongestants, and various other opioid analgesics. The companys lead product candidate, Acurox Tablet, is an orally administered immediate release tablet containing oxycodone HCl as its active analgesic ingredient. Its opioid analgesic product candidates are used to relieve pain while discouraging common methods of opioid product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules; and intentional swallowing of excess quantities of tablets or capsules. The company is also investigating and developing mechanisms to incorporate abuse deterrent characteristics into abused and misused pharmaceutical products through laboratory testing of a product candidate developed with its Impede Technology, which is intended to inhibit the conversion of pseudoephedrine HCl into methamphetamine. Acura Pharmaceuticals, Inc. has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to develop and commercialize various opioid analgesic products utilizing the companys proprietary Aversion Technology in the United States, Canada, and Mexico. The company was founded in 1935 and is based in Palatine, Illinois..

Stereotaxis Inc (NASDAQ:STXS) - Stereotaxis, Inc. designs, manufactures, and markets cardiology instrument control system for use in hospitals interventional surgical suite or interventional lab to treat arrhythmias and coronary artery disease in the United States and internationally. The company offers Niobe system, which comprises Niobe Magnetic Navigation System that navigates catheters, guidewires, and other delivery devices through the blood vessels and chambers of the heart to treatment sites; Navigant, an advanced user interface or physician control center, which helps physicians to visualize and track procedures and to provide instrument control commands that govern the motion of the working tip of the catheter, guidewire, or other interventional device; and Cardiodrive, an automated catheter advancement system to remotely advance and retract the catheter in the patients heart. It also offers Odyssey Enterprise Solution, which provides information solution to manage, control, record, and share procedures across networks; acquire remote view of the lab capturing synchronized procedure data for review of important events during cases; and review recorded cases and create snapshots following procedures for clinical reporting, auditing, and presentation. In addition, the company markets and sells various disposable interventional devices, including catheters, guidewires, and other delivery devices. Stereotaxis markets its products through direct sales force, distributors, and sales agents. It has strategic partnerships with Siemens AG Medical Solutions, Philips Medical Systems, and Biosense Webster, Inc. The company was founded in 1990 and is based in St. Louis, Missouri..

MAJESCO ENTERTAINMENT COMPANY (NASDAQ:COOL) - Majesco Entertainment Company provides interactive entertainment products primarily in the United States and Europe. It offers video game software and other digital entertainment products. The company publishes video games for interactive entertainment hardware platforms, including Nintendo's DS, DSi, and Wii; Sony's PlayStation 2 and PlayStation Portable; Microsoft's Xbox and Xbox 360; and personal computers and other mobile devices. It sells its products primarily to retail chains, specialty retail stores, video game rental outlets, and distributors, as well as international publishers. Majesco Entertainment Company has a strategic partnership with Martha Stewart Living Omnimedia Inc. to develop and produce interactive electronic games. The company was founded in 1998 and is based in Edison, New Jersey..

Somaxon Pharmaceuticals Inc (NASDAQ:SOMX) - Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the in-licensing, development, and commercialization of proprietary branded products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Its principal product Silenor (doxepin) has been approved by the United States Food and Drug Administration for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Solana Beach, California..

Elecsys Corp (NASDAQ:ESYS) - Elecsys Corporation, through its subsidiaries, provides electronic manufacturing services, custom liquid crystal display (LCDs), ultra-rugged mobile computing devices, and wireless remote monitoring solutions to a range of industries worldwide. The company offers electronic design and manufacturing services for original equipment manufacturers (OEMs) in the aerospace, transportation, communications, safety, security, and other industrial product markets. It also designs, develops, and implements ultra-rugged handheld computing solutions, including handheld computers, printers, peripherals, and application software for applications in utilities, transportation logistics, traffic and parking enforcement, route accounting/deliveries, and inspection and maintenance. In addition, the company designs, markets, and provides remote monitoring solutions for the oil and gas pipeline industry, as well as other industries for wireless status monitoring and alarm notification regarding the performance of multiple types of systems over the Internet. Elecsys Corporation was founded in 1991 and is headquartered in Olathe, Kansas..

BG Medicine Inc (NASDAQ:BGMD) - BG Medicine, Inc., a life sciences company, engages in the discovery, development, and commercialization of molecular diagnostics based on biomarkers in the United States. Its product pipeline includes molecular diagnostics for cardiovascular diseases, such as congestive heart failure, coronary stenosis, and vulnerable plaque; cancers; and CNS disorders, including alzheimer's disease and multiple sclerosis, as well as for patients receiving Tysabri, a treatment that is associated with a side effect. The company also provides Avandia, a drug for the treatment of Type II diabetes; and Enbrel and Remicade, which are treatments indicated for autoimmune disorders, such as rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, crohn's disease, and other related conditions. In addition, it offers disease mechanisms, drug mechanisms, drug efficacy, drug toxicity, responder identification, and translational medicine services. The company has a research collaboration with Merck & Co. Inc. for the development and validation of a novel biomarker with potential application in the management of lipid disorders. The company was founded in 2000 as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in November 2004. BG Medicine, Inc. is headquartered in Waltham, Massachusetts..

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net